Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

• Status: Completed
• Trial end date: 2015-07-01
• Target enrollment: 0
• Participant gender: All

Summary

A cohort of patients responsive to treatment with ranibizumab but resistant to

aflibercept were identified in a previously conducted retrospective study. Identified

patients will have their blood drawn for genome wide sequencing. The sequencing

data will be compiled and analyzed in an attempt to identify a common genetic basis

for patients susceptible to ranibizumab but resistant to aflibercept.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Associated Retinal Consultants, Michigan
• Collaborator: Genentech, Inc.
• Treatments: Aflibercept; Ranibizumab

Criteria

Inclusion Criteria:

• Subjects will be eligible if the following criteria are met:

• Demonstrate worsening of exudation when switched from ranibizumab to aflibercept

• Ability to provide written informed consent and comply with study assessments for the full duration of the study

Exclusion Criteria:

• Any other condition that the investigator believes would pose a significant hazard to the subject